Critical Contrast: Presbia (OTCMKTS:LENSF) vs. SI-BONE (NASDAQ:SIBN)

Presbia (OTCMKTS:LENSFGet Free Report) and SI-BONE (NASDAQ:SIBNGet Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Volatility and Risk

Presbia has a beta of 5.91, suggesting that its stock price is 491% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500.


This table compares Presbia and SI-BONE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Presbia N/A N/A N/A
SI-BONE -31.20% -28.22% -20.53%

Analyst Ratings

This is a summary of recent ratings and target prices for Presbia and SI-BONE, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Presbia 0 0 0 0 N/A
SI-BONE 0 0 5 0 3.00

SI-BONE has a consensus target price of $26.33, indicating a potential upside of 60.86%. Given SI-BONE’s higher possible upside, analysts clearly believe SI-BONE is more favorable than Presbia.

Valuation and Earnings

This table compares Presbia and SI-BONE’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Presbia N/A N/A N/A N/A N/A
SI-BONE $138.89 million 4.84 -$43.34 million ($1.14) -14.36

Presbia has higher earnings, but lower revenue than SI-BONE.

Institutional & Insider Ownership

98.1% of SI-BONE shares are held by institutional investors. 74.2% of Presbia shares are held by insiders. Comparatively, 5.4% of SI-BONE shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Presbia beats SI-BONE on 5 of the 9 factors compared between the two stocks.

About Presbia

(Get Free Report)

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.


(Get Free Report)

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

Receive News & Ratings for Presbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia and related companies with's FREE daily email newsletter.